Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of “Hold” by Brokerages

Shares of Vir Biotechnology, Inc. (NASDAQ:VIRGet Rating) have been assigned a consensus recommendation of “Hold” from the eight research firms that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $54.14.

A number of research analysts recently commented on the company. HC Wainwright reissued a “buy” rating and issued a $125.00 price target on shares of Vir Biotechnology in a report on Thursday, July 14th. Morgan Stanley initiated coverage on Vir Biotechnology in a report on Friday. They set an “underweight” rating and a $15.00 target price on the stock. Finally, Barclays reduced their target price on Vir Biotechnology to $67.00 in a report on Monday, August 15th.

Insider Transactions at Vir Biotechnology

In related news, insider Phillip Pang sold 4,991 shares of Vir Biotechnology stock in a transaction on Tuesday, June 21st. The stock was sold at an average price of $24.89, for a total transaction of $124,225.99. Following the completion of the sale, the insider now owns 144,000 shares of the company’s stock, valued at $3,584,160. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Vir Biotechnology news, Director Vicki L. Sato sold 17,915 shares of the firm’s stock in a transaction dated Friday, July 8th. The stock was sold at an average price of $29.06, for a total transaction of $520,609.90. Following the transaction, the director now directly owns 1,470,664 shares in the company, valued at $42,737,495.84. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Phillip Pang sold 4,991 shares of the firm’s stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $24.89, for a total value of $124,225.99. Following the transaction, the insider now owns 144,000 shares in the company, valued at $3,584,160. The disclosure for this sale can be found here. Insiders sold a total of 173,385 shares of company stock valued at $4,767,741 over the last quarter. Company insiders own 22.40% of the company’s stock.

Hedge Funds Weigh In On Vir Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA boosted its holdings in Vir Biotechnology by 0.5% during the second quarter. Massachusetts Financial Services Co. MA now owns 105,665 shares of the company’s stock valued at $2,691,000 after purchasing an additional 537 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Vir Biotechnology by 127.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,000 shares of the company’s stock worth $25,000 after acquiring an additional 560 shares in the last quarter. Handelsbanken Fonder AB boosted its holdings in shares of Vir Biotechnology by 5.4% in the 1st quarter. Handelsbanken Fonder AB now owns 11,800 shares of the company’s stock worth $303,000 after acquiring an additional 600 shares in the last quarter. US Bancorp DE raised its position in Vir Biotechnology by 175.1% in the 2nd quarter. US Bancorp DE now owns 982 shares of the company’s stock worth $25,000 after purchasing an additional 625 shares during the last quarter. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in Vir Biotechnology by 6.8% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 9,983 shares of the company’s stock worth $257,000 after purchasing an additional 635 shares during the last quarter. 64.55% of the stock is currently owned by institutional investors.

Vir Biotechnology Trading Up 0.5 %

Vir Biotechnology stock opened at $22.38 on Monday. The firm has a market capitalization of $2.97 billion, a P/E ratio of 2.79 and a beta of -0.29. The stock has a fifty day moving average price of $27.15 and a 200 day moving average price of $24.90. Vir Biotechnology has a 52 week low of $18.21 and a 52 week high of $58.00.

Vir Biotechnology (NASDAQ:VIRGet Rating) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.41). Vir Biotechnology had a return on equity of 68.86% and a net margin of 52.29%. The firm had revenue of $40.60 million for the quarter, compared to analyst estimates of $211.14 million. During the same quarter in the prior year, the company earned $0.46 earnings per share. The business’s revenue was down 77.1% compared to the same quarter last year. As a group, equities analysts predict that Vir Biotechnology will post 3.14 EPS for the current year.

Vir Biotechnology Company Profile

(Get Rating)

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.

Recommended Stories

Analyst Recommendations for Vir Biotechnology (NASDAQ:VIR)

Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.